Benign prostatic hyperplasia
Conditions
Interventions
Silodosin 4mg once daily after supper
Silodosin 4mg twice daily after breakfast and supper
Sponsors
Study group of voiding dysfunction in North part of Kyushu area
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) IPSS total score >=8 and QOL index >=2 2) OABSS urgency score >=2 and total score >=3
Exclusion criteria
Exclusion criteria: 1) Patients who have a structural disease (e.g. prostatic cancer, bladder neck contracture, urethral stricture). 2) Patients with genitourinary surgery (e.g. TURP) or non-invasive treatment (e.g. balloon dilation, urethral stent, thermotherapy) within previous 6 months. 3) Patients with indwelling urethral cathether or clean-intermittent catheterization. 4) Patients with active urinary tract infections 5) Patients with neurogenic lower urinary tract disorders. 6) Patients having a history of allergic reaction caused by silodosin. 7) Patients who judged as being inadequate for this trial by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| International Prostate Symptom Score (IPSS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Overactive bladder symptom score (OABSS)Uroflowmetry Residual urine volume | — |
Countries
Japan
Contacts
Public ContactRyosuke Takahashi
Kyushu University, Faculty of Medical Science Department of Urology
Outcome results
None listed